| Vol. 6.08 – 4 March, 2022 |
| |
|
|
| Scientists showed that the amino acid-induced Ubr1 activity was necessary to prevent steatosis in mouse livers and cultured human hepatocytes, providing molecular insight into the anti-nonalcoholic fatty liver disease effects of dietary protein/amino acids. [Molecular Cell] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators established a hepatocyte aging model from human induced pluripotent stem cells and developed a method for ex vivo characterization of hepatocyte plasticity. [Hepatology] |
|
|
|
| Hepatocyte nicotinamide phosphoribosyltransferase conveyed key aspects of the fasting response, which selectively dissociated through hepatocyte SIRT1. [Nature Communications] |
|
|
|
| Targeting Mat1a activated the liver-brown adipose tissue axis by increasing NRF2-mediated FGF21 secretion, which prevented obesity, insulin resistance and hepatosteatosis. [Nature Communications] |
|
|
|
| The authors combined optical mapping and whole genome sequencing to explore in depth the nature of structural variants induced by replication stress in cyclin-activated HCCs. [Cancer Research] |
|
|
|
| Researchers explored the potential of antisense oligonucleotides (ASO)-based pyruvate kinase (PKM) splice switching as a targeted therapy for liver cancer. A more potent lead constrained-ethyl/DNA ASO induced PKM splice switching and inhibited the growth of cultured HCC cells. [Cancer Research] |
|
|
|
| Epidermal growth factor (EGF)/EGF receptor (EGFR) signaling upregulated T-box 19 (TBX19) expression via ERK/NF-kB pathway and TBX19 fostered HCC metastasis by enhancing EGFR and Rac family small GTPase 1 (RAC1) expression, which formed an EGF-TBX19-EGFR positive feedback loop. [Oncogene] |
|
|
|
| Scientists reported that the expression of mucin 15 (MUC15) was downregulated in liver tumor-initiating cells, chemoresistance, and recurrent HCC samples. [Cell Death & Disease] |
|
|
|
| 3-Mercaptopyruvate sulfurtransferase (MPST) protein expression was analyzed in HCC tumor tissues and matched adjacent tissues. The effect of MPST on HCC progression was studied in vitro and in vivo. [Liver International] |
|
|
|
| The authors established two lenvatinib-resistant HCC cell lines and identified integrin subunit beta 8 as a critical contributor to lenvatinib resistance in HCC. [Hepatology Communications] |
|
|
|
| Scientists reported a gatekeeper function of the Ras/Erk and NF-κB pathways by working in synergy to suppress liver tumorigenesis. [Molecular Cancer Research] |
|
|
|
| Researchers investigated cytoskeletal regulation in 2D and 3D culture environments using two liver cancer cell lines, SNU-475 and HepG2, chosen for their distinct cytoskeletal features and invasion profiles. [Communications Biology] |
|
|
|
| Investigators evaluated changes in urea cycle enzymes in non-alcoholic fatty liver disease (NAFLD) patients and in two preclinical animal models mimicking this entity. Seventeen liver specimens from NAFLD patients were included for immunohistochemistry and gene expression analysis. [Scientific Reports] |
|
|
|
|
| Scientists summarize the current knowledge on the role of bile acids and the receptors in the development of nonalcoholic fatty liver disease and nnonalcoholic steatohepatitis, especially the functions of farnesoid X receptor in different tissues including liver and intestine. [Acta Pharmacologica Sinica] |
|
|
|
| The authors summarize the latest data of new medications which have completed phase II or III trials for the treatment of nonalcoholic steatohepatitis, and discuss the rationale and preliminary results of several combinatory options. [Acta Pharmacologica Sinica] |
|
|
|
|
| DURECT Corporation announced it dosed the first patient in the European Union as part of its AHFIRM randomized, double-blind, placebo-controlled, multi-center Phase IIb study to evaluate the safety and efficacy of larsucosterol in severe alcohol-associated hepatitis patients. [DURECT Corporation] |
|
|
|
|
| April 8 – 13, 2022 New Orleans, Louisiana, United States |
|
|
|
|
|
| NIH National Heart, Lung, and Blood Institute – Bethesda, Maryland, United States |
|
|
|
| Amsterdam UMC – Amsterdam, Netherlands |
|
|
|
| Gilead Sciences, Inc. – Foster City, California, United States |
|
|
|
| Columbia University – New York, New York, United States |
|
|
|
| University of Washington – Seattle, Washington, United States |
|
|
|
|